Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced multiple presentations at the upcoming Society of Gynecologic Oncology (SGO) 2025 Annual Meeting, scheduled for March 14-17 in Seattle. The presentations include updated clinical data from the Phase 2 DENALI trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC).
Key highlights include an oral presentation by Dr. Fiona Simpkins focusing on Cyclin E1 as a predictive biomarker of azenosertib benefit in PROC patients, scheduled for March 15. Additionally, a poster presentation by Dr. Joanna Guo will showcase preclinical data demonstrating synergistic antitumor effects of azenosertib when combined with microtubule inhibitor-based antibody drug conjugates (ADCs).
Zentalis Pharmaceuticals (NASDAQ: ZNTL) ha annunciato diverse presentazioni all'imminente Annual Meeting della Society of Gynecologic Oncology (SGO) 2025, in programma dal 14 al 17 marzo a Seattle. Le presentazioni includono dati clinici aggiornati dal trial di Fase 2 DENALI di azenosertib in pazienti con cancro ovarico resistente al platino (PROC).
I punti salienti includono una presentazione orale della Dr.ssa Fiona Simpkins che si concentrerà su Cyclin E1 come biomarcatore predittivo del beneficio di azenosertib nei pazienti con PROC, prevista per il 15 marzo. Inoltre, una presentazione poster della Dr.ssa Joanna Guo mostrerà dati preclinici che dimostrano effetti antitumorali sinergici di azenosertib quando combinato con coniugati di farmaci anticorpali basati su inibitori dei microtubuli (ADCs).
Zentalis Pharmaceuticals (NASDAQ: ZNTL) ha anunciado múltiples presentaciones en la próxima Reunión Anual de la Society of Gynecologic Oncology (SGO) 2025, programada del 14 al 17 de marzo en Seattle. Las presentaciones incluyen datos clínicos actualizados del ensayo de Fase 2 DENALI de azenosertib en pacientes con cáncer de ovario resistente al platino (PROC).
Los aspectos destacados incluyen una presentación oral de la Dra. Fiona Simpkins centrada en Cyclin E1 como biomarcador predictivo del beneficio de azenosertib en pacientes con PROC, programada para el 15 de marzo. Además, una presentación en cartel de la Dra. Joanna Guo mostrará datos preclínicos que demuestran efectos antitumorales sinérgicos de azenosertib cuando se combina con conjugados de anticuerpos basados en inhibidores de microtúbulos (ADCs).
젠탈리스 제약 (NASDAQ: ZNTL)은 2025년 부인종양학회(SGO) 연례 회의에서 여러 발표를 할 예정이라고 발표했습니다. 이 회의는 3월 14일부터 17일까지 시애틀에서 열립니다. 발표 내용에는 백금 내성 난소암 (PROC) 환자에서 아제노세르티브의 2상 DENALI 시험의 업데이트된 임상 데이터가 포함됩니다.
주요 하이라이트로는 3월 15일 예정된 Fiona Simpkins 박사의 구두 발표가 있으며, 이 발표는 PROC 환자에서 아제노세르티브의 이점을 예측하는 바이오마커로서 Cyclin E1에 초점을 맞춥니다. 또한 Joanna Guo 박사의 포스터 발표에서는 미세소관 억제제 기반 항체 약물 접합체 (ADCs)와 결합했을 때 아제노세르티브의 시너지 항종양 효과를 보여주는 전임상 데이터가 소개될 것입니다.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) a annoncé plusieurs présentations lors de la prochaine réunion annuelle de la Society of Gynecologic Oncology (SGO) 2025, prévue du 14 au 17 mars à Seattle. Les présentations incluent des données cliniques mises à jour de l'essai de phase 2 DENALI sur azenosertib chez des patients atteints de cancer de l'ovaire résistant au platine (PROC).
Parmi les points forts, une présentation orale de la Dr Fiona Simpkins se concentrera sur Cyclin E1 en tant que biomarqueur prédictif du bénéfice d'azenosertib chez les patients PROC, prévue pour le 15 mars. De plus, une présentation poster de la Dr Joanna Guo mettra en avant des données précliniques démontrant des effets antitumoraux synergiques d'azenosertib lorsqu'il est combiné avec des conjugués anticorps-médicament basés sur des inhibiteurs de microtubules (ADCs).
Zentalis Pharmaceuticals (NASDAQ: ZNTL) hat mehrere Präsentationen bei der bevorstehenden Jahrestagung der Society of Gynecologic Oncology (SGO) 2025 angekündigt, die vom 14. bis 17. März in Seattle stattfinden wird. Die Präsentationen umfassen aktualisierte klinische Daten aus der Phase-2-Studie DENALI zu azenosertib bei Patienten mit platinsensiblem Ovarialkarzinom (PROC).
Wichtige Highlights sind eine mündliche Präsentation von Dr. Fiona Simpkins, die sich am 15. März auf Cyclin E1 als prädiktiven Biomarker für den Nutzen von azenosertib bei PROC-Patienten konzentriert. Darüber hinaus wird eine Posterpräsentation von Dr. Joanna Guo präklinische Daten präsentieren, die synergistische antitumorale Effekte von azenosertib in Kombination mit auf Mikrotubuli-Inhibitoren basierenden Antikörper-Wirkstoff-Konjugaten (ADCs) zeigen.
- WEE1 inhibitor azenosertib shows potential as first-in-class and best-in-class treatment
- Identification of Cyclin E1 as predictive biomarker could improve patient selection
- Demonstrated synergistic effects with ADCs in preclinical studies
- None.
Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC
Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer, to be held on March 14-17 in Seattle, Washington.
Oral Presentation
- Abstract Title: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066)
- Presenter: Fiona Simpkins, M.D.
- Session: Scientific Plenary II: Hitting the Target - Maximizing IMPACT
- Date/Time: Saturday, March 15, 8:25am PST
Poster Presentation
- Abstract Title: The WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Effects With Microtubule Inhibitor–Based Antibody Drug Conjugates (ADCs) in Preclinical Models
- Presenter: Joanna Guo, Ph.D.
- Session: In-Person Poster Session
- Date and Time: Sunday, March 16, 8:15-8:45am and 2:10-3:00pm PST
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Haibo Wang - Chief Business Officer
Ron Moldaver - Investor Relations
ir@zentalis.com
FAQ
What will Zentalis (ZNTL) present at the SGO 2025 Annual Meeting?
When and where is Zentalis (ZNTL) presenting at the SGO 2025 Meeting?
What is the focus of the DENALI trial presentation for ZNTL's azenosertib?
What are the preclinical findings for Zentalis's (ZNTL) azenosertib with ADCs?
